April 7, 2020 — The use of the anti-malarial drug chloroquine to address COVID-19 clients has been halted at many Swedish hospitals because of to described aspect consequences this kind of as cramps and loss of peripheral vision.

Sahlgrenska College Clinic is a single of people amenities. It stopped the use of chloroquine in the therapy of COVID-19 about two months ago.

“There were being reviews of suspected a lot more critical aspect consequences than we 1st thought,” Magnus Gisslen, a professor and main health practitioner at Sahlgrenska College Clinic an infection clinic, instructed the Gothenburg Article on April one, Newsweek described.

“We are unable to rule out critical aspect consequences, specifically from the heart, and it is a tough-dosed drug. In addition, we have no strong evidence that chloroquine has an effect on COVID-19,” Magnus Gisslen stated.

No distinct medication are utilized to address COVID-19 but some people today have advocated the use of the anti-malarial medication chloroquine and hydroxychloroquine.

U.S. President Donald Trump has touted the use of hydroxychloroquine in individual and declared Sunday that the federal government had stockpiled 29 million hydroxychloroquine products for the therapy of COVID-19, Newsweek described.

The use of hydroxychloroquine to address COVID-19 was authorized final thirty day period by the U.S. Foods and Drug Administration, even though scientific research of the two anti-malarial medication have yielded blended results.

For case in point, a single review uncovered they give no more profit to COVID-19 clients who are now getting antiviral medication, Newsweek described.

WebMD News from HealthDay

Copyright © 2013-2018 HealthDay. All legal rights reserved.